Ergoteles’s Avita Medical RCEL Stock Holding History

Ergoteles’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-94,004	Closed	-$495K	–	1801
2022 Q3	$495K	Sell	94,004 -7,959	-8%	-$49.1K	0.02%	765
2022 Q2	$484K	Buy	+101,963	New	+$630K	0.01%	850

Other funds holding RCEL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Ergoteles's RCEL Position: Q4 2022 in Review

Ergoteles sold out of Avita Medical (RCEL) in Q4 2022, closing a stake of 94,004 shares — an estimated $495K sold.

Ergoteles first reported a position in RCEL in Q2 2022 and held it in 2 quarters. The position peaked at $495K in Q3 2022. 51 funds tracked by Wall St. Rank hold RCEL as of Q4 2022.

Ergoteles reported no remaining Avita Medical position as of Q4 2022 after selling out during the quarter.
Ergoteles sold 94,004 Avita Medical shares in Q4 2022, an estimated $495K.
Ergoteles first reported a position in Avita Medical in Q2 2022 and held it in 2 quarters.
Ergoteles's Avita Medical position peaked at $495K in Q3 2022.
51 funds tracked by Wall St. Rank held Avita Medical as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.